A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

NCT07700875 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

391

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: QR12000 Compound Tablets 75 mg
DRUG: QR12000 Compound Tablets 75 mg placebo
DRUG: QR12000 Compound Tablets 150 mg
DRUG: QR12000 Compound Tablets 150 mg placebo
DRUG: QR01019 potassium salt 50 mg
DRUG: QR01019 potassium salt 50 mg placebo
DRUG: Sacubitril / valsartan 200 mg
DRUG: Sacubitril / valsartan 200 mg placebo
DRUG: Valsartan 160 mg
DRUG: Valsartan 160 mg placebo

Sponsor

Wuhan Createrna Science and Technology Co., Ltd